Neurobiological Technologies Sets Date for First Quarter Financial Results
November 04 2008 - 6:30AM
PR Newswire (US)
EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ --
Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII), today
announced it will release its first quarter 2009 financial results,
for the quarter ended September 30, 2008, and host a conference
call on November 6, 2008. Hosting the call will be Paul E. Freiman,
President and Chief Executive Officer, and Matthew M. Loar, Vice
President and Chief Financial Officer. The details for the call are
as follows: Live Call: -- Date: Thursday, November 6, 2007 -- Time:
10:30 a.m. ET, 9:30 a.m. CT, 7:30 a.m. PT -- Dial-in number:
800-309-1245 (U.S.) 719-457-2080 (International) Webcast of Call:
-- A live webcast can be accessed online by going to:
http://investor.shareholder.com/ntii/events.cfm Telephonic Replay:
(Archived for 90 days) A playback of the conference call will be
available from 1:30 PM November 6 (ET) through midnight November 13
(ET). Replay number: 888-203-1112 (U.S. and Canada) / 719-457-0820
(international). Replay access code: 8094663. About Neurobiological
Technologies, Inc. Neurobiological Technologies, Inc.,
(NASDAQ:NTII) is a biopharmaceutical company focused on developing
novel, first-in-class agents for central nervous system conditions
and other serious unmet medical needs. The Company's most advanced
product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical
testing as a novel investigational drug for the treatment of acute
ischemic stroke. Viprinex has multiple mechanisms of action and is
specifically designed to extend the time period that patients can
be treated after the onset of a stroke. Acute ischemic stroke is
one of the most prevalent, debilitating and costly diseases in the
world for which there are few acceptable treatment options. NTI
also has early-stage development programs for Alzheimer's and
Huntington's diseases and rights to receive payments on an approved
drug for Alzheimer's disease and an investigational drug in Phase 3
trials for brain swelling. DATASOURCE: Neurobiological
Technologies, Inc. CONTACT: Matthew M. Loar, CFO, +1-510-595-6000
Web site: http://www.ntii.com/
Copyright
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neurobiological (NASDAQ:NTII)
Historical Stock Chart
From Jul 2023 to Jul 2024